

Anne J Novak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6178044/publications.pdf>

Version: 2024-02-01

124
papers

5,308
citations

147726

31
h-index

88593

70
g-index

125
all docs

125
docs citations

125
times ranked

8651
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690. | 15.2 | 1,224 |
| 2 | Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884. | 3.3 | 853 |
| 3 | Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. <i>Blood</i> , 2004, 103, 689-694. | 0.6 | 474 |
| 4 | Expression of BlyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. <i>Blood</i> , 2004, 104, 2247-2253. | 0.6 | 216 |
| 5 | Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. <i>Blood</i> , 2002, 100, 2973-2979. | 0.6 | 213 |
| 6 | CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 ⁺ T cells. <i>Blood</i> , 2007, 110, 2537-2544. | 0.6 | 181 |
| 7 | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238. | 9.4 | 147 |
| 8 | Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. <i>Oncotarget</i> , 2017, 8, 61425-61439. | 0.8 | 146 |
| 9 | A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , 2010, 207, 2569-2579. | 4.2 | 96 |
| 10 | Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471. | 2.6 | 96 |
| 11 | Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933. | 5.8 | 94 |
| 12 | Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872. | 3.2 | 86 |
| 13 | Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2006, 24, 983-987. | 0.8 | 85 |
| 14 | Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. <i>Blood</i> , 2011, 118, 5540-5549. | 0.6 | 72 |
| 15 | TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5217-5231. | 3.2 | 67 |
| 16 | Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2009, 69, 4217-4224. | 0.4 | 59 |
| 17 | A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751. | 5.8 | 58 |
| 18 | Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i. | 0.9 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | <i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194. | 2.0 | 57 |
| 20 | Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Reports, 2019, 26, 2178-2193.e3. | 2.9 | 57 |
| 21 | Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer Journal, 2019, 9, 22. | 2.8 | 54 |
| 22 | A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood, 2009, 113, 5206-5216. | 0.6 | 46 |
| 23 | PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. Bioinformatics, 2014, 30, 2678-2680. | 1.8 | 43 |
| 24 | Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403. | 1.2 | 41 |
| 25 | Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1. Blood, 2011, 117, e190-e197. | 0.6 | 40 |
| 26 | IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. Blood, 2012, 120, 3774-3782. | 0.6 | 40 |
| 27 | Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Advances, 2018, 2, 1985-1997. | 2.5 | 39 |
| 28 | Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. American Journal of Hematology, 2012, 87, 865-869. | 2.0 | 37 |
| 29 | Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73. | 2.8 | 37 |
| 30 | Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97. | 2.8 | 36 |
| 31 | SIRP α expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. Blood Cancer Journal, 2019, 9, 84. | 2.8 | 35 |
| 32 | RVboost: RNA-seq variants prioritization using a boosting method. Bioinformatics, 2014, 30, 3414-3416. | 1.8 | 34 |
| 33 | Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281. | 2.0 | 33 |
| 34 | Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863. | 0.6 | 28 |
| 35 | Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533. | 3.3 | 28 |
| 36 | Lack of intrafollicular memory CD4 ⁺ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130. | 2.8 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758. | 2.0 | 23 |
| 38 | Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653. | 1.2 | 20 |
| 39 | The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666. | 2.0 | 19 |
| 40 | Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117. | 2.8 | 18 |
| 41 | First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938. | 0.6 | 17 |
| 42 | Non-Hodgkin Lymphoma B-Cells Induce Intratumoral CD4+CD25 ^{hi} T Cells To Express Foxp3 and Gain Regulatory Function.. <i>Blood</i> , 2006, 108, 1724-1724. | 0.6 | 17 |
| 43 | Expression of KLRG1 and CD127 defines distinct CD8 ⁺ subsets that differentially impact patient outcome in follicular lymphoma. , 2021, 9, e002662. | | 16 |
| 44 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187. | 1.1 | 15 |
| 45 | Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182. | 5.8 | 15 |
| 46 | Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. <i>Blood</i> , 2011, 118, 1570-1570. | 0.6 | 15 |
| 47 | Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. <i>Redox Biology</i> , 2020, 36, 101657. | 3.9 | 12 |
| 48 | First report of MYD88 ^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43. | 1.4 | 10 |
| 49 | FCGR3A ^{2A} polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455. | 0.8 | 9 |
| 50 | Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1061-1070. | 1.1 | 8 |
| 51 | Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121. | 0.6 | 7 |
| 52 | Role of B-Lymphocyte Stimulator (BLyS) in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2005, 106, 601-601. | 0.6 | 7 |
| 53 | The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression. <i>Blood</i> , 2015, 126, 2661-2661. | 0.6 | 7 |
| 54 | B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidylinositol 3-kinase pathway in lymphoma B cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 1884-1892. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.. <i>Blood</i> , 2005, 106, 1495-1495. | 0.6 | 6 |
| 56 | Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. <i>Leukemia and Lymphoma</i> , 2017, 58, 2247-2250. | 0.6 | 5 |
| 57 | Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. <i>Clinical Cancer Research</i> , 2020, 26, 5759-5771. | 3.2 | 5 |
| 58 | Interactions Between PD-1 and PD-L1 and PD-L2 Promote Malignant B-Cell Growth in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2013, 122, 4334-4334. | 0.6 | 5 |
| 59 | Chronic lymphocytic leukemia B-cell-derived TNF± impairs bone marrow myelopoiesis. <i>IScience</i> , 2021, 24, 101994. | 1.9 | 4 |
| 60 | Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 603-603. | 0.6 | 4 |
| 61 | Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 440-440. | 0.6 | 4 |
| 62 | Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315. | 0.6 | 3 |
| 63 | Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. <i>Blood</i> , 2005, 106, 2411-2411. | 0.6 | 3 |
| 64 | Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.. <i>Blood</i> , 2008, 112, 2251-2251. | 0.6 | 3 |
| 65 | MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , 2012, 120, 2699-2699. | 0.6 | 3 |
| 66 | Role of CCL5 and Interleukin-6 in the Biology of Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2007, 110, 688-688. | 0.6 | 2 |
| 67 | Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499. | 0.6 | 2 |
| 68 | Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141. | 0.6 | 2 |
| 69 | Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 4322-4335. | 3.2 | 2 |
| 70 | Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221. | 2.5 | 2 |
| 71 | Phase 1 Clinical Study of Atacept in Patients with Relapsed and Refractory B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2722-2722. | 0.6 | 1 |
| 72 | Altered Expression of Immune Checkpoint Molecules Including Programmed Cell Death-1 (PD-1) and Its Ligands PD-L1/PD-L2 in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1772-1772. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299. | 0.6 | 1 |
| 74 | B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenström's Macroglobulinemia. <i>Blood</i> , 2004, 104, 2291-2291. | 0.6 | 1 |
| 75 | APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21. <i>Blood</i> , 2007, 110, 3585-3585. | 0.6 | 1 |
| 76 | Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2009, 114, 925-925. | 0.6 | 1 |
| 77 | Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma. <i>Blood</i> , 2009, 114, 3933-3933. | 0.6 | 1 |
| 78 | Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription. <i>Blood</i> , 2009, 114, 3927-3927. | 0.6 | 1 |
| 79 | Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenström Macroglobulinemia. <i>Blood</i> , 2009, 114, 1691-1691. | 0.6 | 1 |
| 80 | Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991. | 0.6 | 1 |
| 81 | A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 143-143. | 0.6 | 1 |
| 82 | TGF- β 2 Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 1586-1586. | 0.6 | 1 |
| 83 | Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429. | 0.6 | 1 |
| 84 | A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76. | 0.6 | 1 |
| 85 | Treatment Facility Volume and Outcomes in Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622. | 0.6 | 1 |
| 86 | Impact of MYD88L265P mutation Status on Histological Transformation of Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884. | 0.6 | 1 |
| 87 | Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile. <i>Journal of Clinical Oncology</i> , 2020, 38, 8052-8052. | 0.8 | 1 |
| 88 | Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021. | 1.1 | 1 |
| 89 | APRIL Promotes Survival and Proliferation of T Cells: Implications for T-Cell Lymphoma. <i>Blood</i> , 2004, 104, 2652-2652. | 0.6 | 0 |
| 90 | Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms. <i>Blood</i> , 2004, 104, 964-964. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. <i>Blood</i> , 2004, 104, 1397-1397. | 0.6 | 0 |
| 92 | Intratumoral CD4+CD25+ Regulatory T-Cell-Mediated Suppression of Infiltrating CD4+ T-Cells in B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2005, 106, 3312-3312. | 0.6 | 0 |
| 93 | Intratumoral Treg Cells Completely Inhibit the Induction and Function of Tumor-Infiltrating CD8+ T-Cells in B-Cell NHL.. <i>Blood</i> , 2005, 106, 3311-3311. | 0.6 | 0 |
| 94 | Malignant B Cells Skew the Balance between Treg Cell and TH17 Cell Differentiation in B-Cell Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 1347-1347. | 0.6 | 0 |
| 95 | A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. <i>Blood</i> , 2010, 116, 1999-1999. | 0.6 | 0 |
| 96 | A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. <i>Blood</i> , 2010, 116, 468-468. | 0.6 | 0 |
| 97 | Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. <i>Blood</i> , 2010, 116, 3115-3115. | 0.6 | 0 |
| 98 | IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 770-770. | 0.6 | 0 |
| 99 | A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. <i>Blood</i> , 2011, 118, 2642-2642. | 0.6 | 0 |
| 100 | Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2012, 120, 2688-2688. | 0.6 | 0 |
| 101 | Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149. | 0.6 | 0 |
| 102 | Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563. | 0.6 | 0 |
| 103 | IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2012, 120, 1554-1554. | 0.6 | 0 |
| 104 | CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702. | 0.6 | 0 |
| 105 | An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22171-e22171. | 0.8 | 0 |
| 106 | Presence and function of CD14+CD16-HLADR ^{low} monocytes in the peripheral blood of patients with T-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19539-e19539. | 0.8 | 0 |
| 107 | Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131. | 0.6 | 0 |
| 108 | Signal-Regulatory Protein-1 \pm (SIRP-1 \pm) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 2515-2515. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935. | 0.6 | 0 |
| 110 | Isogenic Loss of TNFAIP3 in Waldenstrom Macroglobulinemia Enhances MYD88L265P-Driven Signaling. <i>Blood</i> , 2016, 128, 4100-4100. | 0.6 | 0 |
| 111 | Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138. | 0.6 | 0 |
| 112 | A Role for TNF- α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. <i>Blood</i> , 2019, 134, 4276-4276. | 0.6 | 0 |
| 113 | Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774. | 0.6 | 0 |
| 114 | Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. <i>Blood</i> , 2019, 134, 2764-2764. | 0.6 | 0 |
| 115 | Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919. | 0.6 | 0 |
| 116 | Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923. | 0.6 | 0 |
| 117 | Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. <i>Blood</i> , 2019, 134, 2790-2790. | 0.6 | 0 |
| 118 | Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327. | 0.6 | 0 |
| 119 | T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3522-3522. | 0.6 | 0 |
| 120 | Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1439-1439. | 0.6 | 0 |
| 121 | Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808. | 0.6 | 0 |
| 122 | Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22. | 0.6 | 0 |
| 123 | Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-37. | 0.6 | 0 |
| 124 | High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18. | 0.6 | 0 |